【ductless air conditioner for sunroom】EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This ductless air conditioner for sunroomcompares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.14 per share when it actually produced a loss of $0.14, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
EyePoint Pharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $8.63 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 12.19%. This compares to year-ago revenues of $2.44 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
EyePoint Pharmaceuticals shares have lost about 7.1% since the beginning of the year versus the S&P 500's decline of -3.1%.
What's Next for EyePoint Pharmaceuticals?
While EyePoint Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for EyePoint Pharmaceuticals was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Story continues
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $8.73 million in revenues for the coming quarter and -$0.32 on $48.32 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
View comments
-
Mortgage Rates Are Lowest Ever; 12.8M Should RefinanceConsiderable EBIT improvement in the first two months of 2020WhatsApp no longer supported on millions of phonesWhy Is Vornado (VNO) Up 1.7% Since Last Earnings Report?Companies slammed by coronavirus look to cut contributions to their employees' 401(k)sCohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist PeptidesReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual MeetingBillionaire Warren Buffett Divests Airline Stakes, Sees No ‘Attractive’ InvestmentsAsian Stocks Plummet Amid Oil Price War3 Reasons Growth Investors Will Love Charles River (CRL)
下一篇:Kratos Defense (KTOS) to Post Q1 Earnings: What's in Store?
- ·Ducks Unlimited Canada commends Government’s Fall Economic Statement that recognizes nature in Canada’s economic recovery
- ·RTX CLASS ACTION FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Raytheon Technologies Corporation
- ·Lam Research unveils improved tool to make 3-D chips for phones, devices
- ·Mortgage Rates Are Lowest Ever; 12.8M Should Refinance
- ·Should You Buy AMD Stock?
- ·China's Xi Visits Wuhan, Says Coronavirus Outbreak 'Basically Curbed'
- ·1.9 Million Unemployment Claims; Travel Bets Surge
- ·Coronavirus strands merchant ship crews at sea for months
- ·Best Tarot Cards Reading Online By Kasamba Tarot Readers Experts - How To get Free Love Tarot Readings Online
- ·Oprah tour driving Weight Watchers memberships
- ·Thermon Group Holdings, Inc. to Host Earnings Call
- ·Are Options Traders Betting on a Big Move in Penn National (PENN) Stock?
- ·NetCents Technology Notches Record Transaction Volume, Again
- ·Camber Energy, Inc. and Viking Energy Group, Inc. Amend Definitive Merger Agreement Relating to Their Planned Combination and Provide Update on Status of Merger
- ·Toy CEO says it 'sickens' him that people profit from a shortage of supplies to fight coronavirus
- ·What Is Parker-Hannifin's (NYSE:PH) P/E Ratio After Its Share Price Tanked?
- ·Moderna to supply 100 to 125 mln COVID-19 vaccine doses globally in first quarter
- ·Is Begbies Traynor Group plc's (LON:BEG) High P/E Ratio A Problem For Investors?
- ·LIVE BLOG: How businesses are responding to coronavirus outbreak
- ·Global Flavored Water 2019 - Key Insights and Drivers Behind the Flavored Water Market Performance
- ·Shift Announces Its Intention to Commence an Offer to Exchange Its Publicly Traded Warrants
- ·Technical Enzymes Market 2028 - Global Insights on Trends, Regulatory Landscape, Value Chain Analysis, Key Stakeholders, Growth Drivers and Future Outlook: Adroit Market Research
- ·Post-Pandemic Retirement Planning Strategy Book Launches on June 1, 2020
- ·Wall Street dives 4% as virus pandemic fears intensify
- ·Were Hedge Funds Right About Dumping Retail Value Inc. (RVI)?
- ·Ducks Unlimited Canada commends Government’s Fall Economic Statement that recognizes nature in Canada’s economic recovery
- ·Knowles (KN) Q1 Earnings Beat Estimates, Revenues Down Y/Y
- ·Weekly CEO Buys Highlight
- ·Cargotec completes the ownership change of joint venture in China
- ·U.S. Stocks Set To Open Higher On Final Day Ahead Of U.S. Presidential Election
- ·Earnings Preview: Novanta (NOVT) Q3 Earnings Expected to Decline
- ·OneWater Marine Inc. Announces Fiscal Fourth Quarter and Full-Year 2020 Earnings Release Date and Conference Call Information
- ·Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Groupon, Inc. (GRPN)
- ·These ETF Areas Make Great Investment Choices in June
- ·Coupa Software, Inc. (COUP) Earnings Expected to Grow: Should You Buy?
- ·Calculating The Intrinsic Value Of FFI Holdings Limited (ASX:FFI)